SESSION X: AGGRESSIVE B-CELL LYMPHOMA

Session Chairs: Grzegorz Nowakowski and Astrid Pavlovsky

Frontline DLBCL, Current Approaches and Updates on Ongoing Trials | Grzegorz S Nowakowski, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Sequencing Therapies in Relapsed/Refractory Large B-Cell Lymphoma to Optimize the Chance of Cure | Gilles A Salles, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Bispecific Antibodies in Aggressive B-Cell Lymphoma, Where Do They Fit in? | Krish Patel, MD | Providence Swedish Cancer Institute, Seattle, Washington, USA

What Is Dark Zone Lymphoma and Is It Clinically Relevant?  | David Scott, MBChB, PhD | University of British Columbia, Vancouver, British Columbia, Canada

Managing Burkitt Lymphoma | Jennifer Crombie, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Accessing Novel Therapies for Aggressive Lymphoma | Astrid Pavlovsky, MD | Pavlovsky Center for Hematology, Buenos Aires, Argentina

Oral Abstract | ABCL-503: Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial | Jason R Westin, MD, MS, FACP | MD Anderson Cancer Center, Houston, Texas, USA

Oral Abstract | ABCL-711: Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study | Christopher Yasenchak, MD | Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, USA